Stryker Corporation

New York Stock Exchange
Back to all articles
Bullish +65

Stryker Q2 Earnings Call Highlights

📈 Stryker reported 9% organic sales growth in Q2 with adjusted EPS of $3.69, up 17.9% year over year.

🤖 The company recorded its best-ever quarter for Mako installations, now installed in 47 countries and used in over 2.5 million procedures globally.

⚠️ U.S. vascular sales fell 6.7% due to a supply disruption at the Inari plant, causing backorders expected to normalize by Q3.

💰 Stryker narrowed its full-year guidance to 8.3%-9.3% organic sales growth and $14.95-$15.10 adjusted EPS.

📉 Adjusted gross margin improved 60 basis points to 66%, while operating margin rose 170 basis points to 27.4%.

🚀 The company launched Mako RPS in the U.S. and received FDA approval for Prophecy patient-specific planning guides.

💸 Stryker ended Q2 with $3.5 billion in cash and plans to resume share repurchases alongside its priority on acquisitions.

🤝 The company closed an acquisition of AVS, which has a lithotripsy product pending FDA approval for above-the-knee use.

📉 Adjusted EPS includes tariff refunds but will be offset by cybersecurity remediation costs and raw material pressures in the full year.

👨‍⚕️ CEO Kevin Lobo stated the company exited Q2 with regained momentum and expects a strong second half of the year.

Bullish Signals
  • Stryker achieved record Mako installations in Q2, demonstrating strong demand for its robotic surgery platform.
  • Adjusted gross margin expanded to 66% and operating margin rose to 27.4%, reflecting improved operational efficiency.
  • The company successfully launched Mako RPS and received regulatory approval for new ankle replacement planning tools.
  • Stryker ended the quarter with a robust $3.5 billion cash position, enabling it to resume share repurchases.
  • Organic sales grew across all major segments, including 13.1% growth in Medical and 8.6% in Orthopaedics.
  • The acquisition of AVS adds a promising lithotripsy product line that could expand the Peripheral Vascular market.
Risk Factors
  • U.S. vascular sales declined 6.7% due to a significant supply disruption causing backorders at the Inari plant.
  • The company narrowed its full-year outlook, citing cybersecurity-related manufacturing losses and idle costs.
  • Cybersecurity remediation spending and IT costs will offset some of the tariff refund benefits over the full year.
Full Analysis
Stryker Corporation reported strong second-quarter results with 9% organic sales growth and adjusted earnings per share of $3.69, representing a 17.9% year-over-year increase. The company achieved record installations for its Mako robotic system and saw high-single-digit growth in its MedSurg, Neurotechnology, and Orthopaedics segments as operations recovered from an earlier cybersecurity incident. Despite the overall strength, U.S. vascular sales declined 6.7% due to a supply disruption at one of its Peripheral Vascular plants, which created significant backorders. CEO Kevin Lobo noted that while the company regained momentum with increased production and strong capital demand, recovery in the vascular segment is expected to take time through the second half of the year. Stryker narrowed its full-year outlook, projecting organic sales growth between 8.3% and 9.3% and adjusted EPS between $14.95 and $15.10. The company ended the quarter with approximately $3.5 billion in cash and generated $1.8 billion in operating cash flow year-to-date. Management plans to resume share repurchases while maintaining acquisitions as its top capital-allocation priority. The article highlights specific product successes, including the launch of Mako RPS and approvals for new ankle replacement planning tools. Additionally, Stryker closed an acquisition of AVS, which holds a lithotripsy product pending FDA approval. The company also faces ongoing costs related to cybersecurity remediation and raw material pressures, though it expects tariff refunds to provide some benefit.